keyword
MENU ▼
Read by QxMD icon Read
search

Macular edema anti-VEGF

keyword
https://www.readbyqxmd.com/read/28931763/reversible-retinal-vessel-closure-from-vegf-induced-leukocyte-plugging
#1
Yuanyuan Liu, Jikui Shen, Seth D Fortmann, Jiangxia Wang, Dietmar Vestweber, Peter A Campochiaro
Clinical trials in patients with macular edema due to diabetic retinopathy or retinal vein occlusion (RVO) have shown that suppression of VEGF not only improves macular edema, but also reopens closed retinal vessels, prevents progression of vessel closure, and improves retinopathy. In this study, we show the molecular basis for those clinical observations. Increased retinal levels of VEGF in mice cause plugging of retinal vessels with leukocytes, vessel closure, and hypoxia. Suppression of VEGF reduces leukocyte plugging, causing reperfusion of closed vessels...
September 21, 2017: JCI Insight
https://www.readbyqxmd.com/read/28924438/central-retinal-vein-occlusion-in-2-patients-using-antipsychotic-drugs
#2
Koichiro Taki, Teruyo Kida, Masanori Fukumoto, Takaki Sato, Hidehiro Oku, Tsunehiko Ikeda
PURPOSE: To report our findings in 2 patients who developed a central retinal vein occlusion (CRVO) and were chronic users of antipsychotic medications. CASE PRESENTATION: Case 1 was a 62-year-old woman who had a sudden reduction of vision in her right eye to 20/2,000. Her fundus showed signs of an impending CRVO with marked macular edema. She had been taking antipsychotic drugs (quetiapine fumarate and risperidone) for about 2 years. She refused anti-VEGF therapy for her macular edema but selected systemic kallidinogenase...
May 2017: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28916115/-retinal-vein-occlusions
#3
REVIEW
A Pierru, J-F Girmens, E Héron, M Paques
Retinal venous occlusions comprise central retinal vein occlusion, hemiretinal vein occlusions, and branch retinal vein occlusions. They are associated with arterial hypertension and glaucoma. Retinal vein occlusions occur more frequently in males, at a median age of 55. The pathogenesis of retinal venous occlusions remains obscure. The clinical presentation of the disease is variable. In most cases, there is a unilateral visual loss over days with a painless, white and quiet eye. However, retinal venous occlusions may also present as an abrupt and profound loss of vision, or be asymptomatic...
September 12, 2017: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/28902336/switching-anti-vegf-drugs-in-the-treatment-of-diabetic-macular-edema
#4
Touka Banaee, Mohammed Ashraf, Felipe F Conti, Rishi P Singh
Since their introduction in the late 2000s, anti-vascular endothelial growth factor (VEGF) agents have become the first-line choice for center-involved diabetic macular edema (DME). Even with its proven effectiveness, there are still cases that do not respond satisfactorily. In those cases, a treatment option is to change to another anti-VEGF drug. In this paper, the authors review studies on switching between different anti-VEGF drugs in the treatment of persistent DME. An extensive bibliographic review was done using PubMed, Embase, and Scopus...
September 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28881146/health-economic-evaluation-of-fluocinolone-acetonide-190%C3%A2-%C3%A2%C2%B5g-implant-in-people-with-diabetic-macular-edema
#5
Sarah E Holden, Craig J Currie, David R Owens
OBJECTIVES: To assess healthcare resource use and costs of treating people with clinically significant diabetic macular edema (DME) with fluocinolone acetonide (FAc) 190 µg intravitreal implant in routine clinical practice. METHODS: The retrospective Iluvien Clinical Evidence (ICE-UK) study collected data on people prescribed the FAc implant in any one of 13 ophthalmology centers between April 1, 2013 and April 15, 2015. Data were collected for 12 months before and after implantation...
October 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28839510/combined-intravitreal-dexamethasone-implant-and-micropulse-yellow-laser-for-treatment-of-anti-vegf-resistant-diabetic-macular-edema
#6
Ahmed Hosni Abd Elhamid
PURPOSE: To report the efficacy and safety of combined intravitreal dexamethasone implant and micropulse laser for anti-VEGF resistant diabetic macular edema. PATIENTS AND METHODS: Prospective, non-controlled study that was conducted for twenty eyes with center-involved diabetic macular edema not responding to anti-VEGF therapy. Ozurdex intravitreal implant was injected to all eyes with subsequent micropulse yellow laser one month after the injection. All eyes were followed up after one, three, four, six, nine and twelve months...
2017: Open Ophthalmology Journal
https://www.readbyqxmd.com/read/28831613/sustained-intraocular-pressure-elevation-in-eyes-treated-with-intravitreal-injections-of-anti-vascular-endothelial-growth-factor-for-diabetic-macular-edema-in-a-real-life-setting
#7
S Vo Kim, F Fajnkuchen, V Sarda, L Qu-Knafo, B Bodaghi, A Giocanti-Aurégan
PURPOSE: The aim of this study was to investigate the sustained intraocular pressure (IOP) elevation after repeated anti-VEGF intravitreal injections (IVI) in patients with diabetic macular edema (DME). METHODS: A retrospective study included 140 eyes without prior glaucoma, treated with at least three anti-VEGF injections for DME between 2012 and 2016. IOP elevation was defined by an increase above baseline IOP by ≥6 mmHg. Baseline IOP was defined as the mean of IOP values before treatment initiation...
August 22, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28828763/laser-and-anti-vascular-endothelial-growth-factor-agent-treatments-for-retinal-arterial-macroaneurysm
#8
Yen-Yi Chen, Lo-Yi Lin, Pei-Yao Chang, Fang-Ting Chen, Elsa L C Mai, Jia-Kang Wang
PURPOSE: To describe the efficacy of laser and intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents for patients with symptomatic retinal arterial macroaneurysm (RAM). DESIGN: From 2009 to 2016, we collected patients with exudative or hemorrhagic RAM all treated by focal laser photocoagulation. METHODS: Nd:YAG laser was performed in patients with subinternal limiting membrane (sub-ILM) hemorrhage. Intravitreal anti-VEGF agents were given in eyes with macular exudation as adjuncts...
August 22, 2017: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/28828184/switch-of-intravitreal-therapy-for-macular-edema-secondary-to-retinal-vein-occlusion-from-anti-vegf-to-dexamethasone-implant-and-vice-versa
#9
Amelie Pielen, Anima Desiree Bühler, Sonja Ute Heinzelmann, Daniel Böhringer, Thomas Ness, Bernd Junker
PURPOSE: To evaluate the anatomical and functional outcome of intravitreal dexamethasone implant for macular edema secondary to central (C) or branch (B) retinal vein occlusion (RVO) in patients with persistent macular edema (ME) refractory to intravitreal antivascular endothelial growth factor (VEGF) treatment compared to treatment naïve patients and to dexamethasone-refractory eyes switched to anti-VEGF. METHODS: Retrospective, observational study including 30 eyes previously treated with anti-VEGF (8 CRVO, 22 BRVO, mean age 69 ± 10 yrs), compared to 11 treatment naïve eyes (6 CRVO, 5 BRVO, 73 ± 11 yrs) and compared to dexamethasone nonresponders (2 CRVO, 4 BRVO, 69 ± 12)...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28819567/systemic-associations-with-residual-subretinal-fluid-after-ranibizumab-in-diabetic-macular-edema
#10
Meng-Ju Tsai, Yi-Ting Hsieh, Elizabeth P Shen, Yi-Jie Peng
PURPOSE: To investigate the impact of systemic diseases on the occurrence of subretinal fluid (SRF) in diabetic macular edema (DME) and prognostic factors for residual SRF following three consecutive monthly intravitreal ranibizumab. METHODS: Ninety-seven eyes from 68 patients with DME who completed 3 consecutive monthly injections of ranibizumab were enrolled. Systemic parameters mainly included chronic kidney disease (CKD), hypertension, HbA1c, and insulin dependence...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28811936/real-life-management-of-patients-with-retinal-vein-occlusion-using-i-macula-web-platform
#11
Massimo Nicolò, Monica Bonetto, Raffaella Rosa, Donatella Musetti, Maria Musolino, Carlo Enrico Traverso, Mauro Giacomini
AIM: Real-life evaluation in the management of patients affected by macular edema secondary to retinal vein occlusion. MATERIAL AND METHODS: A retrospective, observational study using the I-Macula Web platform. RESULTS: Thirty-five patients (37 eyes; 15 females and 20 male) affected by RVO were analysed. At 12 months, there was a statistically significant improvement of best-corrected visual acuity (p = 0.0235) and central macular thickness (p < 0...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28803666/-inefficacy-of-aflibercept-in-the-treatment-of-idiopathic-macular-telangiectasia-type-2%C3%A2-without-neovascularization
#12
J Bénichou, V Soler, D Denis, F Matonti
Idiopathic macular telangectasia type 2 is a rare disease consisting primarily of bilateral macular capillary telangiectasia, alterations of the ellipsoid zone and intraretinal cysts that may appear as cystoid macular edema in the absence of neovascularization. Our goal was to study the efficacy of aflibercept in the treatment of these cysts. Thus, we performed a series of three intravitreal injections of aflibercept in the right eye of a woman with a typical presentation of macular telangectasia type 2 complicated by cystoid macular edema without neovascularization...
September 2017: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/28803326/short-term-results-of-endovascular-surgery-with-tissue-plasminogen-activator-injection-for-central-retinal-vein-occlusion
#13
Masaaki Ishida, Shinya Abe, Takuya Nakagawa, Atsushi Hayashi
PURPOSE: To examine the effects of retinal endovascular surgery (REVS) with tissue plasminogen activator injection into the retinal vein in central retinal vein occlusion (CRVO) eyes. METHODS: Sixteen consecutive CRVO patients with macular edema and decreased visual acuity who were referred to Toyama University Hospital between March 2014 and February 2016 were included in this study. Changes in visual acuity (VA) and central retinal thickness (CRT) were evaluated up to 6 months after REVS...
August 12, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28731494/subthreshold-micropulse-laser-reduces-anti-vegf-injection-burden-in-patients-with-diabetic-macular-edema
#14
Elad Moisseiev, Sam Abbassi, Sumeer Thinda, Joseph Yoon, Glenn Yiu, Lawrence S Morse
PURPOSE: To evaluate the efficacy of micropulse laser in the early treatment of diabetic macular edema (DME) and its associated burden of anti-vascular endothelial growth factor (VEGF) injections. METHODS: This retrospective comparative study compared a group of 19 eyes with DME treated with micropulse laser to a matched control group of 19 eyes with DME treated with ranibizumab injections without micropulse laser. Recorded parameters included previous medical and ocular history, previous and subsequent ranibizumab injections administered for DME, visual acuity (VA), central macular thickness throughout the follow-up period, and the occurrence of any complications...
July 20, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28717786/setting-priorities-for-diabetic-retinopathy-clinical-research-and-identifying-evidence-gaps
#15
Jimmy T Le, Susan Hutfless, Tianjing Li, Neil M Bressler, James Heyward, Ava K Bittner, Adam Glassman, Kay Dickersin
PURPOSE: Prioritizing comparative effectiveness research may contribute to obtaining answers that clinicians perceive they need and may minimize research that could be considered wasteful. Our objective was to identify evidence gaps and set priorities for new systematic reviews and randomized controlled trials for managing diabetic retinopathy (DR), including diabetic macular edema (DME). DESIGN: Cross-sectional study. PARTICIPANTS: Diabetic Retinopathy Clinical Research Network (DRCR...
March 2017: Ophthalmology retina
https://www.readbyqxmd.com/read/28646440/a-comparison-of-three-different-intravitreal-treatment-modalities-of-macular-edema-due-to-branch-retinal-vein-occlusion
#16
Havva Erdogan Kaldırım, Serpil Yazgan
PURPOSE: To compare the efficacy of intravitreal injection of ranibizumab, dexamethasone implant and aflibercept for the management of macular edema (ME) related to branch retinal vein occlusion (BRVO). METHODS: This retrospective and comparative study included 62 eyes of 62 patients with BRVO and ME. Patients received one of the following treatments: 0.5 mg ranibizumab (group 1, n = 22), 0.7 mg dexamethasone implant (group 2, n = 20) and 2 mg aflibercept (group 3, n = 20)...
June 23, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28642823/visualization-of-changes-in-the-foveal-avascular-zone-in-both-observed-and-treated-diabetic-macular-edema-using-optical-coherence-tomography-angiography
#17
Aditya Gill, Emily D Cole, Eduardo A Novais, Ricardo N Louzada, Talisa de Carlo, Jay S Duker, Nadia K Waheed, Caroline R Baumal, Andre J Witkin
BACKGROUND: Central vision loss in diabetic retinopathy is commonly related to diabetic macular edema (DME). The objective of this study was to describe changes between consecutive visits on optical coherence tomography angiography (OCTA) of the foveal avascular zone (FAZ) in eyes with DME. METHODS: 20 eyes from 14 patients with DME were imaged on 2 successive clinic visits separated by at least 1 month. The mean interval between visits was 3.2 months. The only intervention used was intravitreal anti-VEGF in 11 eyes; the others were observed over time without treatment...
2017: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/28638337/intravitreal-anti-vascular-endothelial-growth-factor-for-macular-edema-due-to-complex-retinal-arterial-macroaneurysms
#18
Caroline Bormann, Jens Heichel, Ute Hammer, Anke Habermann, Thomas Hammer
INTRODUCTION: Complex retinal arterial macroaneurysms (RAM) are often accompanied by hemorrhage and/or affect the macula. We evaluated the effect of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy using ranibizumab or aflibercept with or without laser photocoagulation in the treatment of macular edema due to RAM. METHODS: A case report of two patients with secondary macular edema caused by RAM is presented. The first case was a 76-year-old female treated with two 0...
January 2017: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28625129/triamcinolone-acetonide-suppresses-inflammation-and-facilitates-vascular-barrier-function-in-human-retinal-microvascular-endothelial-cells
#19
Shunsuke Imai, Tomohiro Otsuka, Akira Naito, Masamitsu Shimazawa, Hideaki Hara
BACKGROUND: Diabetic macular edema (DME) is resulted from the retinal microvascular leakage that accompanies the breakdown of blood-retinal barrier. Triamcinolone acetonide (TA) is a therapeutic agent for DME, but since the detailed mechanism of action of TA is not known, part of its action was examined. METHODS: In vitro model to enhance the permeability of human retinal microvascular endothelial cells (HRMECs) was constructed by using DME-related cytokines such as vascular endothelial growth factor (VEGF), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β)...
2017: Current Neurovascular Research
https://www.readbyqxmd.com/read/28601428/vegf-production-and-signaling-in-m%C3%A3-ller-glia-are-critical-to-modulating-vascular-function-and-neuronal-integrity-in-diabetic-retinopathy-and-hypoxic-retinal-vascular-diseases
#20
Yun-Zheng Le
Müller glia (MG) are major retinal supporting cells that participate in retinal metabolism, function, maintenance, and protection. During the pathogenesis of diabetic retinopathy (DR), a neurovascular disease and a leading cause of blindness, MG modulate vascular function and neuronal integrity by regulating the production of angiogenic and trophic factors. In this article, I will (1) briefly summarize our work on delineating the role and mechanism of MG-modulated vascular function through the production of vascular endothelial growth factor (VEGF) and on investigating VEGF signaling-mediated MG viability and neural protection in diabetic animal models, (2) explore the relationship among VEGF and neurotrophins in protecting Müller cells in in vitro models of diabetes and hypoxia and its potential implication to neuroprotection in DR and hypoxic retinal diseases, and (3) discuss the relevance of our work to the effectiveness and safety of long-term anti-VEGF therapies, a widely used strategy to combat DR, diabetic macular edema, neovascular age-related macular degeneration, retinopathy of prematurity, and other hypoxic retinal vascular disorders...
June 21, 2017: Vision Research
keyword
keyword
36615
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"